Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

A new study confirms a link between Novo Nordisk's Ozempic and an increased risk of NAION, a rare, irreversible form of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...

Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision ...